Jan Braess

TL;DR: This study provides a comprehensive overview of the spectrum, clinical associations, and prognostic relevance of recurrent driver gene mutations in a large cohort representing a broad spectrum and age range of intensively treated AML patients.

TL;DR: Older and younger patients with AML show modest differences in their risk profiles and equally no dose response to intensified chemotherapy under harmonized conditions, but their observed fundamental difference in outcome across all subgroups remains unexplained.

TL;DR: Biallelic disruption of the N and C terminus ofCEBPA is required for the favorable clinical outcome of CEBPA-mutated patients and represents a distinct molecular subtype of CN-AML with a different frequency of associated gene mutations.

TL;DR: Reporter gene assays showed reduced capacity to enhance CEBPA-mediated activation of transcription, suggesting that the GATA2 ZF1 mutations may collaborate with biCEPBA mutations to deregulate target genes during malignant transformation, providing evidence for a genetically distinct subgroup of CN-AML.

TL;DR: High ERG expression levels emerged as a strong negative prognostic factor and provided prognostic information in addition to established molecular markers in a large, homogeneous CN-AML patient cohort.